REG - Futura Medical PLC - Result of General Meeting and Total Voting Rights

Futura MedicalAnnouncement

02/12/2025 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251202:nRSB9038Ja&default-theme=true

RNS Number : 9038J  Futura Medical PLC  02 December 2025

2 December 2025

Futura Medical plc

("Futura", "the Company" or "the Group")

Result of General Meeting and Total Voting Rights

Futura Medical (AIM:FUM), the consumer healthcare Group behind Eroxon®, that
specialises in the development and global commercialisation of innovative
and clinically proven sexual health products, announces that following the
General Meeting held earlier today at the Company's registered offices at 10
a.m., all resolutions set out in the notice of General Meeting contained in
the Circulated dated 13 November 2025 were duly passed.

Resolutions 1 and 3 were proposed as ordinary resolutions and resolutions 2, 4
and 5 were proposed as special resolutions. The total number of votes received
on each resolution were as follows:

             For                              Against
 Resolution  Votes For       % of votes cast  Votes Against  % of votes cast  Votes withheld  Total votes cast
 1             154,316,685   99.23            1,203,457      0.77             198,143         155,718,285
 2           154,329,985     99.23              1,200,657    0.77             187,643         155,718,285
 3           154,316,685     99.23            1,203,457      0.77             198,143         155,718,285
 4           154,316,485     99.23            1,203,657      0.77             198,143         155,718,285
 5           154,314,875     99.23            1,205,267      0.77             198,143         155,718,285

 

Accordingly, all conditions precedent relating to the proposed placing and
subscription (the "Fundraise") announced on 13 November 2025 have now been met
(save for Subsequent Admission).

Application has been made for 13,200,000 Subscription Shares and 231,800,000
Conditional Placing Shares to be admitted to trading on AIM, it is expected
that the admission will become effective and that dealings will commence at
8.00 a.m. on or around 4 December 2025.

Total Voting Rights

Following the Admission, the Company will have 581,120,659 ordinary shares of
£0.002 each in issue.

The Company does not hold any shares in treasury and all of the Ordinary
Shares have equal voting rights. Therefore, the figures above represent the
total voting rights in the Company and this figure may be used by Shareholders
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the voting rights of the Company under the FCA's Disclosure Guidance and
Transparency Rules

Unless otherwise stated, capitalised terms not otherwise defined in the text
of this announcement have the same meanings ascribed to them as in the
announcement released by the Company on 13 November 2025.

- ENDS -

For further information, please contact:

 

 Futura Medical plc                          +44 (0) 1483 685 670

 Alex Duggan CEO

 Angela Hildreth FD/COO
 Panmure Liberum - Nominated Adviser         +44 (0) 20 3100 2000

 Will Goode / Emma Earl /Mark Rogers
 Turner Pope Investments (TPI) Ltd - Broker  +44 (0) 20 3657 0050

 Guy McDougall / Andrew Thacker
 Alma Strategic Communications               +44 (0)20 3405 0205

 Rebecca Sanders-Hewett

 Sam Modlin                                  futura@almastrategic.com

 

About Futura Medical plc

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and products WSD4000 and
Eroxon(®) Intense. Our core strength lies in our research, development and
commercialisation of topically delivered gel formulations in sexual health
products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5
men globally across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Around 60% of women experience at least one symptom of sexual dysfunction, and
only one in four women seek professional help, and remain chronically
underserved.

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of Erectile Dysfunction ("ED"). The highly differentiated
product, which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten minutes, addresses significant
unmet needs in the ED market. Eroxon(®) has been nominated for a number of
healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMZZMGZMZVGKZM



            Copyright 2019 Regulatory News Service, all rights reserved